直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Federal Circuit Clarifies Conception Standard for Inventorship, Vacates-in-part PTAB Judgment

June 23, 2025

Authored and Edited by Christopher B. Anderson; Sonja W. Sahlsten; Jack McLaughlan*

In Regents of the Univ. of Cal. v. Broad Inst., Inc., No. 2022-1594 (Fed. Cir. May 12, 2025), the Federal Circuit vacated in part a determination by the Patent Trial and Appeal Board in a patent interference proceeding, ruling that the Board incorrectly applied the legal standard for conception.

Both The Regents of the University of California (“Regents”), and The Broad Institute (“Broad”) asserted priority of invention for patent claims relating to CRISPR-Cas9 Systems that contain a “single guide” RNA that edits or cleaves DNA in eukaryotic cells.

The Board awarded Broad priority based on an October 5, 2012, publication after rejecting Regents’ earliest asserted conception date of March 1, 2012, and reduction to practice date of August 9, 2012, based on Regents’ statements of uncertainty about whether its experiments would translate to human cells.

On appeal, the Federal Circuit vacated the Board’s decision regarding conception. It concluded that the Board conflated conception and reduction to practice by improperly focusing on Regents’ statements of uncertainty and requiring Regents’ scientists to know their invention would work to prove conception. As the Federal Circuit clarified, knowledge that an invention will work is relevant not to conception, but to reduction to practice. The Board also erred by focusing on Regents’ expressions of doubt regarding their experimental success. Instead, the conception analysis must turn on whether Regents’ scientists had formed the idea in a final form such that only the application of ordinary skill in the art was needed to reduce it to practice. The Court separately affirmed the Board’s analysis regarding written description support and denied Broad’s cross-appeal on claim construction as moot.

Tags

Final Written Decision

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Offices

Reston, VA

Washington, DC

Contacts

Christopher B. Anderson
Associate
Reston, VA
+1 571 203 2765
Email
Sonja W. Sahlsten
Partner
Washington, DC
+1 202 408 4329
Email

*Jack McLaughlan is a Summer Associate at Finnegan. 

Copyright © Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Conference

Best Practices and Tech in Intellectual Property Conference 2026

May 17, 2026

Tel Aviv

Seminar

IP Strategy at the Crossroads: Technology, Enforcement, and Contracts

May 15, 2026

Taipei

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP